Prevalence of HIV-1 Integrase Strand Transfer Inhibitor Resistance in Treatment-Naïve Voluntary Counselling and Testing Clients by Population Sequencing and Illumina Next-Generation Sequencing in Taiwan

References

• Davy-Mendez T, Eron JJ, Brunet L, Zakharova O, Dennis AM, Napravnik S. New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations. AIDS. 2018;32(17):2593–2603. doi:10.1097/QAD.000000000000199030134298
   PubMed Web of Science ®Google Scholar
• Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363–371. doi:10.1016/S1473-3099(11)70032-921354861
   PubMed Web of Science ®Google Scholar
• Rupérez M, Pou C, Maculuve S, et al. Determinants of virological failure and anti-retroviral drug resistance in Mozambique. J Antimicrob Chemother. 2015;70(9):2639–2647. doi:10.1093/jac/dkv14326084302
   PubMed Web of Science ®Google Scholar
• Weng YW, Chen IT, Tsai HC, et al. Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan. BMC Infect Dis. 2019;19(1):741. doi:10.1186/s12879-019-4389-131443633
   PubMed Web of Science ®Google Scholar
• Liu WC, Chang LH, Wu PY, et al. Seroincidence of HIV and prevalence of transmitted drug resistance of HIV-1 strains among persons seeking voluntary counselling and testing in Taiwan. J Int AIDS Soc. 2014;17(Suppl 4):19758. doi:10.7448/IAS.17.4.1975825397503
   PubMed Web of Science ®Google Scholar
• Chang SY, Lin PH, Cheng CL, et al. Prevalence of Integrase Strand Transfer Inhibitors (INSTI) resistance mutations in taiwan. Sci Rep. 2016;6(1):35779. doi:10.1038/srep3577927779200
   PubMed Web of Science ®Google Scholar
• Tsai HC, Chen IT, Wu KS, et al. HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan. Oncotarget. 2018;9(38):24927–24935. doi:10.18632/oncotarget.2483729861843
   PubMedGoogle Scholar
• Noguera-Julian M, Edgil D, Harrigan PR, Sandstrom P, Godfrey C, Paredes R. Next-generation human immunodeficiency virus sequencing for patient management and drug resistance surveillance. J Infect Dis. 2017;216(suppl_9):S829–S833. doi:10.1093/infdis/jix39728968834
   PubMed Web of Science ®Google Scholar
• Tsai HC, Chou PY, Wann SR, Lee SS, Chen YS. Chemokine co-receptor usage in HIV-1-infected treatment-naïve voluntary counselling and testing clients in Southern Taiwan. BMJ Open. 2015;5(4):e007334. doi:10.1136/bmjopen-2014-007334
   Web of Science ®Google Scholar
• Canducci F, Barda B, Ceresola E, et al. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clin Microbiol Infect. 2011;17(6):928–934. doi:10.1111/j.1469-0691.2010.03375.x20854427
   PubMed Web of Science ®Google Scholar
• Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204(11):1811–1815. doi:10.1093/infdis/jir63621984737
   PubMed Web of Science ®Google Scholar
• Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. update of the drug resistance mutations in HIV-1. Top Antivir Med. 2019;2019(27):111–121.
   Google Scholar
• Stanford University HIV Drug Resistance Datbase. Available from: https://hivdb.stanford.edu. Version 8.7, Accessed 1019, 2018.
   Google Scholar
• Ji H, Liang B, Knox C, et al. Development of a data processing portal in support of tagged pooled pyrosequencing-based HIV drug resistance analysis. 22nd Annual Canadian Conference on HIV/AIDS Research 2013; Vancouver, Canada: Can J Infect Dis Med Microbiol.
   Google Scholar
• Langmead B, Salzberg S. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–359. doi:10.1038/nmeth.192322388286
   PubMed Web of Science ®Google Scholar
• Simen BB, Simons JF, Hullsiek KH, et al. Low abundance drug resistant viral variants in chronically HIV-infected antiretroviral-naive patients significantly impact treatment. J Infect Dis. 2009;199(5):693–701. doi:10.1086/59673619210162
   PubMed Web of Science ®Google Scholar
• Johnson JA, Li J-F, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5(7):e158. doi:10.1371/journal.pmed.005015818666824
   PubMed Web of Science ®Google Scholar
• Li JZ, Paredes R, Ribaudo H, et al. Minority HIV-1 drug resistance mutations and the risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011;305(13):1327–1335. doi:10.1001/jama.2011.37521467286
   PubMed Web of Science ®Google Scholar
• Moscona R, Ram D, Wax M, et al. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000–2014. J Int AIDS Soc. 2017;20(1):21846. doi:10.7448/IAS.20.1.2184628799325
   PubMed Web of Science ®Google Scholar
• Nguyen T, Fofana DB, Lê MP, et al. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. J Antimicrob Chemother. 2018;73(9):2485–2492. doi:10.1093/jac/dky19829873733
   PubMed Web of Science ®Google Scholar
• Dalmat RR, Makhsous N, Pepper GG, et al. Limited marginal utility of deep sequencing for HIV drug resistance testing in the age of integrase inhibitors. J Clin Microbiol. 2018;56(12):e01443–18. doi:10.1128/JCM.01443-1830305383
   PubMed Web of Science ®Google Scholar